Indian pharmaceutical stocks experiencing recent dips should be seen as strategic buying opportunities rather than red flags for investors, according to Kranthi Bathini, Equity Strategist at WealthMills Securities. Bathini emphasizes that while individual drugmakers face short-term pressures, the broader investment case for the pharma and healthcare sectors remains robust.
Long-Term Momentum Intact
The strategist highlighted the "fabulous rally" witnessed across both pharma and healthcare segments over the past 12 to 18 months, noting that hospital stocks have also sustained significant gains. This resilience positions the sectors as attractive options for investors seeking earnings visibility and defensive plays in a volatile market. Bathini points to consistent performance, strong balance sheets, and stable demand trends as key drivers.
Dips as Tactical Openings
Bathini views any current weakness in select pharma counters as a short-term, sentiment-driven reaction, not a fundamental reversal. "Any consolidation or any kind of decline in these stocks, it gives a good opportunity for the investors for a medium to longer term basis," he stated.
He clarified that despite mixed news flow concerning specific companies—such as regulatory setbacks for Cipla, data updates for Sun Pharma, a commercial arrangement ending for Piramal Pharma, and acquisition news for Aurobindo Pharma—the overall sector signal remains positive. Bathini concluded, "One can buy pharma stocks. Still there is steam left in the pharma stocks" for the medium to long term, urging investors to focus on sector durability over daily headlines.